Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Pharming Group NV (PHGUF : OTC)
 
 • Company Description   
Pharming Group NV develops innovative therapeutics for the treatment of genetic disorders, specialty products for surgical indications and nutritional products. The advanced technologies of the Company include innovative and validated platforms for the production of protein therapeutics, technology and processes for the purification and formulation of its products. Its primary product Ruconest (R) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with hereditary angioedema in the European Union countries, Norway, Iceland and Liechtenstein. Pharming Group NV is headquartered in Leiden, the Netherlands.

Number of Employees: 426

 
 • Price / Volume Information   
Yesterday's Closing Price: $1.15 Daily Weekly Monthly
20 Day Moving Average: 74 shares
Shares Outstanding: 671.07 (millions)
Market Capitalization: $771.73 (millions)
Beta: 0.60
52 Week High: $1.19
52 Week Low: $0.75
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 15.00% 10.26%
12 Week 27.78% 11.97%
Year To Date 17.17% 10.66%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
Darwinweg 24
-
Leiden,P7 2333 CR
NLD
ph: 31-0-71-524-7400
fax: 31-0-71-524-7445
investor@pharming.com http://www.pharming.com
 
 • General Corporate Information   
Officers
Sijmen de Vries - Chief Executive Officer
Richard Peters - Chairperson
Deborah Jorn - Vice Chairperson
Mireille Sanders - Chief Operations Officer
Jeroen Wakkerman - Chief Financial Officer

Peer Information
Pharming Group NV (CORR.)
Pharming Group NV (RSPI)
Pharming Group NV (CGXP)
Pharming Group NV (BGEN)
Pharming Group NV (GTBP)
Pharming Group NV (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: N69603145
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/07/25
Share - Related Items
Shares Outstanding: 671.07
Most Recent Split Date: 3.00 (0.10:1)
Beta: 0.60
Market Capitalization: $771.73 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/07/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.58
Price/Cash Flow: 153.03
Price / Sales: 2.41
EPS Growth
vs. Year Ago Period: 0.00%
vs. Previous Quarter: -300.00%
Sales Growth
vs. Year Ago Period: 42.29%
vs. Previous Quarter: -14.68%
ROE
06/30/25 - -
03/31/25 - -6.01
12/31/24 - -5.04
ROA
06/30/25 - -
03/31/25 - -3.23
12/31/24 - -2.61
Current Ratio
06/30/25 - -
03/31/25 - 2.76
12/31/24 - 3.77
Quick Ratio
06/30/25 - -
03/31/25 - 2.00
12/31/24 - 3.02
Operating Margin
06/30/25 - -
03/31/25 - -4.14
12/31/24 - -3.70
Net Margin
06/30/25 - -
03/31/25 - -4.14
12/31/24 - -3.70
Pre-Tax Margin
06/30/25 - -
03/31/25 - -1.14
12/31/24 - -2.86
Book Value
06/30/25 - -
03/31/25 - 0.32
12/31/24 - 0.33
Inventory Turnover
06/30/25 - -
03/31/25 - 0.60
12/31/24 - 0.61
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.51
12/31/24 - 0.48
Debt-to-Capital
06/30/25 - -
03/31/25 - 33.89
12/31/24 - 32.23
 

Powered by Zacks Investment Research ©